Current Headlines

  1. ZZ Biotech Announces NIH-Funded Phase II Trial For Stroke Drug

    ZZ Biotech announced that the National Institutes of Health and Broadview Ventures will support a multi-center Phase II clinical trial of its experimental drug 3K3A-APC in patients suffering from acute ischemic stroke.

  2. The Lancet Publishes Phase III Trial Of Nevaxar For Thyroid Cancer

    Bayer HealthCare and Onyx Pharmaceuticals, an Amgen subsidiary, announced that The Lancet published online results from its Phase III DECISION trial. Trial results showed that Nevaxar (sorafenib) tablets significantly extended the time patients with locally recurrent or metastatic, progressive, differentiated thyroid carcinoma that is refractory to radioactive iodine treatment lived without their disease worsening (progression-free survival (PFS)).

  3. Lpath And WRAIR Partner To Study Brain Injury Drug

    Lpath, an antibody-platform company focusing on bioactive lipid-targeted therapeutics, and scientists from the Center for Military Psychiatry and Neuroscience, Walter Reed Army Institute of Research (WRAIR) announced the start of a collaborative research agreement study for brain injury drug Lpathomab.

  4. AbbVie Files NDA For All-Oral Hep C Regimen

    AbbVie announced it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its investigational all-oral, interferon-free regimen for the treatment of adult patients with chronic genotype 1 (GT1) hepatitis C virus (HCV) infection.

  5. Aastrom Biosciences Acquires Sanofi Cell Therapy And Regenerative Medicine Business

    Aastrom Biosciences announced that it has signed a definitive agreement to acquire Sanofi’s Cell Therapy and Regenerative Medicine (CTRM) business for $6.5 million.

  6. Researchers Identify Astrocytes’ New Role In Neuronal Communication

    Scientists from the University of California, Los Angeles, found that brain cells called astrocytes might play a part in neuronal communication only during bursts of neuron activity.

  7. Biomarker Leads To Cancer Drug Resistance And Tumor Formation

    Researchers from the University of California, San Diego School of Medicine have identified CD61, a biomarker present on the surface of drug-resistant tumors, which they believe could shed light on why many drugs used in the treatment of lung, breast, and pancreatic cancer also encourage drug resistance and eventually lead to tumor formation in patients.

  8. NSTDA Discovers New Anti-Malaria Drug

    Thailand’s state run National Science and Technology Development Agency, or NSTDA, has developed a new medication for malaria that will soon be tested in clinical trials. The medication, a chemical called P218, was designed to target the malarial enzyme and stop the disease’s DNA from replicating. Researchers have said that the drug can completely destroy malaria parasites, and it won’t be expensive for the country to manufacture.

  9. Pilgrim Software's 10th Global Customer Conference Lauds 'Success Through Quality'

    Pilgrim Software, Inc., a leading provider of cloud and on-premise enterprise quality management solutions, hosted its tenth worldwide customer conference this month.

  10. Sarepta Therapeutics To File NDA For Muscular Dystrophy Drug

    Sarepta Therapeutics, a company focused on developing RNA-based treatments, announced its intent to file a New Drug Application for eteplirsen for the treatment of Duchenne muscular dystrophy (DMD) by the end of 2014.